For those interested in the biopharma sector Alpha Cognition Inc. ( $ACOG.V ACOGF ) is a company that is in the clinical stages of developing treatments for Alzheimer's Disease, ALS, and other under-served neurodegenerative diseases.
The two main drugs they are developing are called ALPHA-1062 and ALPHA-602.
Alpha-1062 is very similar to a drug that was developed by J&J and approved in the mid-2000s.
However, $ACOG's version is optimized to minimize the side effects that the J&J version had (which were quite severe).
Alpha-602 is a progranulin (a type of protein) gene therapy drug.
Alpha-602 has been shown to help with a number of disease states and according to $ACOG's CEO could possibly become a curative option for ALS.
Additionally, $ACOG gained $14.4M from their Canadian IPO that they plan to use for the commercialization of their drugs.
Between the potential of the drugs that they are creating as well as the fact that the financing is there I think this company is a good bet in this space.
$ACOG is up 3.5% trading at $1.19, MC $73.18 M